Status:
COMPLETED
Tadalafil in Subjects With Mild to Moderate Hypertension
Lead Sponsor:
Eli Lilly and Company
Collaborating Sponsors:
ICOS Corporation
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Purpose: The primary objective of this study is to evaluate the efficacy and safety of tadalafil when administered once daily at doses of 5 and 20 mg to adult subjects for 8 weeks with mild to moderat...
Eligibility Criteria
Inclusion
- Have a documented medical history of hypertension.
- Have cuff seated diastolic blood pressure values greater than or equal to 95 and less than or equal to 104 mm at study entry
- Have a negative serum pregnancy test at the time of enrollment and agree to use two medically reliable methods of contraception until study completion, if female is of child-bearing potential, between menarche and 1 year post menopause and not surgically sterilized.
- Are able to comply with study procedures and visits
Exclusion
- Have resistant hypertension or systolic hypertension.
- Are obese, defined as having body mass index (BMI) greater than or equal to 35.
- Are females who are pregnant or breast feeding.
- Have a history of severe renal insufficiency or significant thyroid, renal or hepatic disease.
- Have a glycosylated hemoglobin A1c (HbA1c) greater than or equal to 10% during the screening period.
- Have significant anemia.
- Have a significant or unstable cardiac history such as history of heart attack, unstable angina, or stroke within 6 months of study entry, history of angina that was treated with long- or short-acting nitrates within 90 days of study entry, history of coronary artery bypass graft surgery or cardiac angioplasty within 90 days of study entry, history of abnormal heart rhythms such as sick sinus syndrome or 2nd- or 3rd-degree AV block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia, a history of recurrent ventricular tachycardia, or symptomatic bradycardia, a history of sudden cardiac arrest.
- Have symptomatic heart failure requiring treatment, or significant disease of the heart valves.
- Have been treated for severe asthma, bronchospasm, or COPD within 3 months of study entry.
- Have severe peripheral vascular disease.
- Have a documented diagnosis of sleep apnea.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00157326
Start Date
September 1 2005
End Date
June 1 2006
Last Update
October 25 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Bothell, Washington, United States